Skip to main content
SpringerLink
Log in

Conjunctive Therapy to Reduce the Occurrence of Coronary Reocclusion after Thrombolytic Treatment of AMI

  • Chapter
Fibrinolytics and Antifibrinolytics

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 146))

  • 162 Accesses

Abstract

Thrombolyticx therapy aims to dissolve the occlusive thrombus present in over 90% of acute myocardial infractions (AMI) (Dewood et al. 1980; Falk 1983; Davies and Thomas 1989; Fuster et al. 1992; reviewed by Rentrop 2000). Prompt reperfusion reduces infarct size, preserves ventricular function, and reduces mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI (1985) Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood 65:32–40

    PubMed  CAS  Google Scholar 

  • Adgey AA (1998) An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J 19 [Suppl D]:D10–D21

    PubMed  CAS  Google Scholar 

  • AIMS Trial Study Group (1988) Effect of intravenous APSAC on mortality after acute myocardial infarction. Preliminary report of a placebo-controlled clinical trial. Lancet 1:545–549

    Google Scholar 

  • Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, McIntire LV (1993) Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 81:1263–1276

    PubMed  CAS  Google Scholar 

  • Ambrose JA (1992) Plaque disruption and the acute coronary syndromes of unstable angina and myocardial infarction: if the substrate is similar, why is the clinical presentation different? J Am Coll Cardiol 19:1653–1658

    Article  PubMed  CAS  Google Scholar 

  • Antman EM, for the TIMI 9B Investigators (1996) Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 94:911–921

    Article  PubMed  CAS  Google Scholar 

  • Antman EM, for the TIMI 9A Investigators (1994) Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 90:1624–1630

    Article  PubMed  CAS  Google Scholar 

  • Antman EM, Cohen M (1999) Newer antithrombin agents in acute coronary syndromes. Am Heart J 138 [Suppl]:S563–S569

    Google Scholar 

  • Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht H-J, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E, for the TIMI 14 Investigators (1999) Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99:2720–2732

    Article  PubMed  CAS  Google Scholar 

  • Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M (1992) Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA). J Am Coll Cardiol 20:513–519

    Article  PubMed  CAS  Google Scholar 

  • Aronson DL, Chang P, Kessler CM (1992) Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 85:1706–1712

    Article  PubMed  CAS  Google Scholar 

  • Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101:1206–1218

    CAS  Google Scholar 

  • Atar S, Luo H, Nagai T, Siegel RJ (1999) Ultrasonic thrombolysis: catheter-delivered and transcutaneous applications. Eur J Ultrasound 9:39–54

    Article  PubMed  CAS  Google Scholar 

  • Bachmann F, Savcic M, Hauert J, Geudelin JB, Kieffer G, Cariou R (1996) Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. Eur Heart J 17 [Suppl]:263 (Abstract)

    Google Scholar 

  • Back LD, Radbill JR, Crawford DW (1977) Analysis of pulsatile, viscous blood flow through diseased coronary arteries of man. J Biomech 10:339–353

    Article  PubMed  CAS  Google Scholar 

  • Badimon L, Badimon JJ (1989) Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 84:1134–1144

    Article  PubMed  CAS  Google Scholar 

  • Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V (1986) Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 6:312–320

    Article  PubMed  CAS  Google Scholar 

  • Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V (1988) Platelet thrombus formation on collagen type I. A model of deep vessel injury. Influence of blood rheology, von Willebrand factor, and blood coagulation. Circulation 78:1431–1442

    Article  PubMed  CAS  Google Scholar 

  • Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, on behalf of the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 316:1337–1343

    Article  PubMed  CAS  Google Scholar 

  • Bär FW, Meyer J, Michels R, Uebis R, Lange S, Barth H, Groves R, Vermeer F (1993) The effect of taprostene in patients with acute myocardial infraction treated with thrombolytic therapy: results of the START study. Saruplase Taprostene Acute Reocclusion Trial. Eur Heart J 14:1118–1126

    Article  PubMed  Google Scholar 

  • Barbagelata NA, Granger CB, Oqueli E, Suárez LD, Borruel M, Topol EJ, Califf RM (1997) TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Am Heart J 133:273–282

    Article  PubMed  CAS  Google Scholar 

  • Barbash GI, Hod H, Roth A, Miller HI, Rath S, Zahav YH, Modan M, Zivelin A, Laniado S, Seligsohn U (1989) Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 64:1231–1235

    Article  PubMed  CAS  Google Scholar 

  • Bassand J-P, Cariou R, Grollier G, Kragten J, Wolf J-E, Heyndrickx GR (1999) Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction. Semin Thromb Hemost 25 [Suppl 2]:69–75

    PubMed  CAS  Google Scholar 

  • Behar S, Hod H, Kaplinsky E, for the ARGAMI-2 Study Group (1998) Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations — ARGAMI-2 Study. Circulation 98:453 (Abstract)

    Google Scholar 

  • Bleich SD, Nichols TC, Schumacher RR, Cook DH, Tate DA, Teichman SL (1990) Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66:1412–1417

    Article  PubMed  CAS  Google Scholar 

  • Boersma E, Maas ACP, Deckers JW, Simoons ML (1996) Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 348:771–775

    Article  PubMed  CAS  Google Scholar 

  • Cairns JA, Fuster V, Gore J, Kennedy JW (1995) Coronary thrombolysis. Chest 108 [Suppl]:401S–423S

    Article  PubMed  CAS  Google Scholar 

  • Cannon CP (1995) Thrombin inhibitors in acute myocardial infarction. Cardiol Clin 13:421–433

    PubMed  CAS  Google Scholar 

  • Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E (1994) A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993–1003

    Article  PubMed  CAS  Google Scholar 

  • Cercek B, Lew AS, Hod H, Yano J, Reddy NK, Ganz W (1986) Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 74:583–587

    Article  PubMed  CAS  Google Scholar 

  • Chesebro JH, Fuster V (1991) Dynamic thrombosis and thrombolysis. Role of antithrombins. Circulation 83:1815–1817

    Article  PubMed  CAS  Google Scholar 

  • Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E (1987) Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76:142–154

    Article  PubMed  CAS  Google Scholar 

  • Chesebro JH, Toschi V, Lettino M, Gallo R, Badimon JJ, Fallon JT, Fuster V (1995) Evolving concepts in the pathogenesis and treatment of arterial thrombosis. Mt Sinai J Med 62:275–286

    PubMed  CAS  Google Scholar 

  • Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group (1994) Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 89:81–88

    Article  PubMed  CAS  Google Scholar 

  • Collen D (1993) Towards improved thrombolytic therapy. Lancet 342:34–36

    Article  PubMed  CAS  Google Scholar 

  • Coller BS (1995) Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 92:2373–2380

    Article  PubMed  CAS  Google Scholar 

  • Dangas G, Badimon JJ, Coller BS, Fallon JT, Sharma SK, Hayes RM, Meraj P, Ambrose JA, Marmur JD (1998) Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vase Biol 18:1342–1349

    Article  CAS  Google Scholar 

  • Davies MJ, Thomas AC (1985) Plaque Assuring — the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 53:363–373

    Article  PubMed  CAS  Google Scholar 

  • de Bono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Bescos LL, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M, for the European Cooperative Study Group (1992) Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial (ECSG-6). Br Heart J 67:122–128

    Article  PubMed  Google Scholar 

  • de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Coulter SA, Anderson K, Scherer J, Frey MJ, Van der Wieken R, Van de Werf F, Braunwald E, for the TIMI 14 Investigators (2000) Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 101:239–243

    Article  PubMed  Google Scholar 

  • Dellborg M, Topol EJ, Swedberg K (1991) Dynamic QRS complex and ST segment vectorcardiographic monitoring can identify vessel patency in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J 122:943–948

    Article  PubMed  CAS  Google Scholar 

  • DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897–902

    Article  PubMed  CAS  Google Scholar 

  • Di Pasquale P, Lo Verso P, Bucca V, Cannizzaro S, Scalzo S, Maringhini G, Rizzo R, Paterna S (1999) Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther 13:423–428

    Article  PubMed  Google Scholar 

  • Drake TA, Morrissey JH, Edgington TS (1989) Selective cellular expression of tissue factor in human tissues. Am J Pathol 134:1087–1097

    PubMed  CAS  Google Scholar 

  • Eisenberg PR, Sherman LA, Jaffe AS (1987) Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 10:527–529

    Article  PubMed  CAS  Google Scholar 

  • Eisenberg PR, Sobel BE, Jaffe AS (1992) Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 19:1065–1069

    Article  PubMed  CAS  Google Scholar 

  • EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group (1993) Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 342:767–772

    Article  Google Scholar 

  • Falk E (1983) Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 50:127–134

    Article  PubMed  CAS  Google Scholar 

  • Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671

    Article  PubMed  CAS  Google Scholar 

  • Faulds D, Sorkin EM (1994) Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 48:583–598

    Article  PubMed  CAS  Google Scholar 

  • Ferguson JJ (1999) Meeting highlights. Highlights of the 71st scientific sessions of the American Heart Association. Circulation 99:2486–2491

    Article  PubMed  CAS  Google Scholar 

  • Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343:311–322

    Google Scholar 

  • Fitzgerald DJ, Catella F, Roy L, FitzGerald GA (1988) Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 77:142–150

    Article  PubMed  CAS  Google Scholar 

  • Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, Siegbahn A, Swahn E, Venge P, Wallentin L (1999) Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction — a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 33:627–633

    Article  PubMed  CAS  Google Scholar 

  • Fung AY, Lorch G, Cambier PA, Hansen D, Titus BG, Martin JS, Lee JJ, Every NR, Hallstrom AP, Stock-Novack D, Scherer J, Weaver WD, and the ESCALAT Investigators (1999) Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. Am Heart J 138:696–704

    Article  PubMed  CAS  Google Scholar 

  • Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA (1991) Human platelet/-erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 5:2304–2312

    PubMed  CAS  Google Scholar 

  • Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326:242–250 &-310–318

    Article  PubMed  CAS  Google Scholar 

  • Gersh BJ (1999) Optimal management of acute myocardial infarction at the dawn of the next millennium. Am Heart J 138 [Suppl 2]:S188–S202

    Google Scholar 

  • Gertz DS, Kragel AH, Kalan JM, Braunwald E, Roberts WC, and the TIMI Investigators (1990) Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. Am J Cardiol 66:904–909

    Article  PubMed  CAS  Google Scholar 

  • Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, Alexander B, Diver DJ, McCabe CH, Flaker GC, Bairn DS, Braunwald E (1995) Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis In Myocardial Infarction (TIMI) 4 Trial. J Am Coll Cardiol 25:582–589

    Article  PubMed  CAS  Google Scholar 

  • Glick A, Kornowski R, Michowich Y, Koifman B, Roth A, Laniado S, Keren G (1996) Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 77:1145–1148

    Article  PubMed  CAS  Google Scholar 

  • Golino P, Ashton JH, Glas Greenwalt P, McNatt J, Buja LM, Willerson JT (1988) Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 77:678–684

    Article  PubMed  CAS  Google Scholar 

  • Gouin I, Lecompte T, Morel M-C, Lebrazi J, Modderman PW, Kaplan C, Samama MM (1992) In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis. Circulation 85:935–941

    Article  PubMed  CAS  Google Scholar 

  • Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth S, Lambrew C, Bovill EG, for the GUSTO-I Hemostasis Substudy Group (1998) Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. J Am Coll Cardiol 31:497–505

    Article  PubMed  CAS  Google Scholar 

  • Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ, for the GUSTO-I Investigators (1996) Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 93:870–878

    Article  PubMed  CAS  Google Scholar 

  • GREAT Group (1993) Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. BMJ 305:548–553

    Google Scholar 

  • Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (1990) GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 336:65–71

    Google Scholar 

  • Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397–402

    Google Scholar 

  • Harrington RA (1998) Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial. J Am Coll Cardiol 32:2003–2010

    Article  Google Scholar 

  • Harrington RA (1999) Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. Am Heart J 138 (Suppl.):S276–S286

    Article  CAS  Google Scholar 

  • Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V (1989) Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79:657–665

    Article  PubMed  CAS  Google Scholar 

  • Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V (1990) Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 82:1476–1484

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L (1995) Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 108 [Suppl]:258S–275S

    Article  PubMed  CAS  Google Scholar 

  • Hochman JS, Wali AU, Gavrila D, Sim MJ, Malhotra S, Palazzo AM, De La Fuente B (1999) A new regimen for heparin use in acute coronary syndromes. Am Heart J 138:313–318

    Article  PubMed  CAS  Google Scholar 

  • Hoffmeister HM, Szabo S, Kastner C, Beyer ME, Helber U, Kazmaier S, Wendel HP, Heller W, Seipel L (1998) Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin. Circulation 98:2527–2533

    Article  PubMed  CAS  Google Scholar 

  • Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators (1990) A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 323:1433–1437

    Article  PubMed  CAS  Google Scholar 

  • Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) Investigators (1992) Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 20:31–35

    Article  PubMed  CAS  Google Scholar 

  • ISIS (International Studies of Infarct Survival) Pilot Study Investigators (1987) Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 8:634–642

    Google Scholar 

  • ISIS-3 (Third International Study of Infarct Survival) Collaborative Group (1992) ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 339:753–770

    Article  Google Scholar 

  • Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D (1989) Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 79:920–928

    Article  PubMed  CAS  Google Scholar 

  • Jang I-K, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP, Bazzino O, Viamonte VM, Norbady R, Liprandi AS, Massey TJ, Dinsmore R, Schwarz RP Jr, and the MINT Investigators (1999) A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 33:1879–1885

    Article  PubMed  CAS  Google Scholar 

  • Jang Y, Lincoff AM, Plow EF, Topol EJ (1994) Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 24:1591–1601

    Article  PubMed  CAS  Google Scholar 

  • Kaplan K, Davison R, Parker M, Mayberry B, Feiereisel P, Salinger M (1987) Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. Am J Cardiol 59:241–244

    Article  PubMed  CAS  Google Scholar 

  • Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL, for the TEAM-2 Investigators (1992) Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 19:1–10

    Article  PubMed  CAS  Google Scholar 

  • Kawano K, Aoki I, Aoki N, Homori M, Maki A, Hioki Y, Hasumura Y, Terano A, Arai T, Mizuno H, Ishikawa K (1998) Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface Pselectin expression. Am Heart J 135:268–271

    Article  PubMed  CAS  Google Scholar 

  • Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK (1985) The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction: a 12 month follow-up report. N Engl J Med 212:1073–1078

    Article  Google Scholar 

  • Kereiakes DJ, McDonald M, Broderick T, Roth EM, Whang DD, Martin LH, Howard WL, Schneider J, Shimshak T, Abbottsmith CW (2000) Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes. Am Heart J 139 [Suppl]:S53–S60

    Article  PubMed  CAS  Google Scholar 

  • Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ (1989) Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 80:1718–1725

    Article  PubMed  CAS  Google Scholar 

  • Kim CB, Braunwald E (1993) Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation 88:2426–2436

    Article  PubMed  CAS  Google Scholar 

  • Kizer JR, Cannon CP, McCabe CH, Mueller HS, Schweiger MJ, Davis VG, Perritt R, Antman EM, for the TIMI Investigators (1999) Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Am Heart J 137:79–92

    Article  PubMed  CAS  Google Scholar 

  • Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Cokkinos DV, Simoons ML, Boersma E, Topol EJ, Califf RM, Harrington RA, for the PURSUIT Investigators (2000) Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 101:751–757

    Article  PubMed  CAS  Google Scholar 

  • Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ (1993) Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 22:381–389

    Article  PubMed  CAS  Google Scholar 

  • Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ (1998) Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98:2829–2835

    Article  PubMed  CAS  Google Scholar 

  • Krucoff MW, Green CE, Satler LF, Miller FC, Pallas RS, Kent KM, Del Negro AA, Pearle DL, Fletcher RD, Rackley CE (1986) Noninvasive detection of coronary artery patency using continuous ST-segment monitoring. Am J Cardiol 57:916–922

    Article  PubMed  CAS  Google Scholar 

  • Kruik JH, Verheugt FWA, Hacke W, von Kummer R, Van de Werf F, for the COBALT Investigators (1998) Correlation of activated partial thromboplastin time at 6 hours after thrombolysis for acute myocardial infarction and hemorrhagic stroke in the COBALT trial. Circulation 98 [Suppl I]:562–562 (Abstract)

    Article  Google Scholar 

  • Kunitada S, FitzGerald GA, Fitzgerald DJ (1992) Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 79:1420–1427

    PubMed  CAS  Google Scholar 

  • LATE Study Group (1993) Late assessment of thrombolytic efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 342:759–766

    Article  Google Scholar 

  • Lee CD, Mann KG (1989) Activation/inactivation of human factor V by plasmin. Blood 73:185–190

    PubMed  CAS  Google Scholar 

  • Lee LV, for the TIMI 6 Investigators (1995) Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 75:7–13

    Article  PubMed  CAS  Google Scholar 

  • Lidón RM, Théroux P, Lespérance J, Adelman B, Bonan R, Duval D, Lévesque J (1994) A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 89:1567–1572

    Article  PubMed  Google Scholar 

  • Lincoff AM, Topol EJ (1993) Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 88:1361–1374

    Article  PubMed  CAS  Google Scholar 

  • Lucore CL, Sobel BE (1988) Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 77:660–669

    Article  PubMed  CAS  Google Scholar 

  • McRedmond JP, Harriott P, Walker B, Fitzgerald DJ (2000) Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of proteaseactivated receptor-1. Blood 95:1301–1308

    PubMed  CAS  Google Scholar 

  • Madan M, Berkowitz SD, Tcheng JE (1998) Glycoprotein IIb/IIIa integrin blockade. Circulation 98:2629–2635

    Article  PubMed  CAS  Google Scholar 

  • Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB, for the AMISTAD Investigators (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34:1711–1720

    Article  PubMed  CAS  Google Scholar 

  • Mailhac A, Badimon JJ, Fallon JT, Fernández-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L (1994) Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 90:988–996

    Article  PubMed  CAS  Google Scholar 

  • Mann KG, Tracy PB, Nesheim ME (1985) Assembly and function of prothrombinase complex on synthetic and natural membranes. In: Oates JA, Harwiger J, Ross R (eds). Interaction of platelets with the vessel wall, American Physiologic Society, Washington D.C., pp 47–57

    Google Scholar 

  • Marder VJ, Sherry S (1988) Thrombolytic therapy: current status. N Engl J Med 318:1512–1520,1585–1595

    Article  PubMed  CAS  Google Scholar 

  • Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB (1996) Identification of active tissue factor in human coronary atheroma. Circulation 94:1226–1232

    Article  PubMed  CAS  Google Scholar 

  • Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61–68

    Article  PubMed  CAS  Google Scholar 

  • Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, Topol EJ, for the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators (1998) Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. J Am Coll Cardiol 31:1493–1498

    Article  PubMed  CAS  Google Scholar 

  • Meyer BJ, Badimon JJ, Mailhac A, Fernández-Ortiz A, Chesebro JH, Fuster V, Badimon L (1994) Inhibition of growth of thrombus on fresh mural thrombus. Targeting optimal therapy. Circulation 90:2432–2438

    Article  PubMed  CAS  Google Scholar 

  • Michaels AD, Maynard C, Every NR, Barron HV, for the National Registry of Myocardial Infarction 2 Participants (1999) Early use of ACE inhibitors in the treatment of acute myocardial infarction in the United States: experience from the National Registry of Myocardial Infarction 2. Am J Cardiol 84:1176–1181

    Article  PubMed  CAS  Google Scholar 

  • Mruk JS, Zoldhelyi P, Webster MWI, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH (1996) Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. Circulation 93:792–799

    Article  PubMed  CAS  Google Scholar 

  • Neuhaus K-L, Molhoek GP, Zeymer U, Tebbe U, Wegscheider K, Schröder R, Camez A, Laarman GJ, Grollier GM, Lok DJ, Kuckuck H, Lazarus P, for the HIT-4 Investigators (1999) Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 34:966–973

    Article  PubMed  CAS  Google Scholar 

  • Neuhaus K-L, von Essen R, Tebbe U, Jessel A, Heinrichs H, Mäurer W, Döring W, Harmjanz D, Kötter V, Kalhammer E, Simon H, Horacek T (1994) Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 90:1638–1642

    Article  PubMed  CAS  Google Scholar 

  • Niewiarowski S, Senyi AF, Gillies P (1973) Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. J Clin Invest 52:1647–1659

    Article  PubMed  CAS  Google Scholar 

  • Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, and the TAMI Study Group (1990) Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 82:781–791

    Article  PubMed  CAS  Google Scholar 

  • Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ, for the IMPACT-AMI Investigators (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 95:846–854

    Article  PubMed  CAS  Google Scholar 

  • Ohman EM, Lincoff AM, Bode C, Bachinsky WB, Ardissino D, Betriu A, Schildcrout JS, Oliverio R, Barnathan E, Sherer J, Sketch MS, Topol EJ (1998) Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: preliminary results from the GUSTO-4 pilot (SPEED) dose-ranging trial. Circulation 98 [Suppl I]:504 (Abstract)

    Google Scholar 

  • Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER (1988) Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 72:616–620

    PubMed  CAS  Google Scholar 

  • Peter K, Straub A, Kohler B, Nordt T, Ruef J, Moser M, Schwarz M, Kübler W, Bode C (2000) Platelet activation as a potential mechanism of Gp IIb/IIIa inhibitorinduced thrombocytopenia. J Am Coll Cardiol 35 [Suppl]:371A (Abstract)

    Article  Google Scholar 

  • Peters RJG, Spickler W, Theroux P, White H, Gibson M, Molhoek PG, Hirsch J, Weitz JI, Weaver D (2000) Randomized comparison of vasoflux, a novel anticoagulant, and heparin as adjunctive therapy to streptkinase for acute myocardial infarction. J Am Coll Cardiol 35 [Suppl]:373A (Abstract)

    Google Scholar 

  • Potter van Loon BJ, Rijken DC, Brommer EJ, van der Maas APC (1992) The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 67:101–105

    Google Scholar 

  • Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berghaus G (1997) Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 86:373–383

    Article  PubMed  Google Scholar 

  • Raghu C, Peddeswara Rao P, Seshagiri Rao D (1999) Protective effect of intravenous magnesium in acute myocardial infarction following thrombolytic therapy. Int J Cardiol 71:209–215

    Article  PubMed  CAS  Google Scholar 

  • Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators (1988) Thrombolysis in myocardial infarction (TIMI) trial. Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1–11

    Article  PubMed  CAS  Google Scholar 

  • Rapold HJ, de Bono D, Arnold AER, Arnout J, De Cock F, Collen D, Verstraete M, for the European Cooperative Study Group (1992) Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 85:928–934

    Article  PubMed  CAS  Google Scholar 

  • Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A (1989) Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infaction with recombinant tissue-type plasminogen activator. Circulation 79:980–989

    Article  PubMed  CAS  Google Scholar 

  • Reiner JS, Lundergan CF, van den Brand M, Boland J, Thompson MA, Machecourt J, Py A, Pilcher GS, Fink CA, Burton JR, Simoons ML, Califf RM, Topol EJ, Ross AM, for the GUSTO Angiographic Investigators (1994) Early angiography cannot predict postthrombolytic coronary reocclusion: Observations from the GUSTO angiographic study. J Am Coll Cardiol 24:1439–1444

    Article  PubMed  CAS  Google Scholar 

  • Rentrop KP (2000) Thrombi in acute coronary syndromes: revisited and revised. Circulation 101:1619–1626

    Article  PubMed  CAS  Google Scholar 

  • Ronner E, Dykun Y, van den Brand MJBM, Van der Wieken LR, Simoons ML (1998a) Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J 19:1608–1616

    Article  PubMed  CAS  Google Scholar 

  • Ronner E, van Kesteren HAM, Zijnen P, Tebbe U, Molhoek P, Cuffie C, Veltri E, Lorenz T, Neuhaus K, Simoons ML (1998b) Combined therapy with streptokinase and integrilin. Eur Heart J 19 [Suppl]:123 (Abstract)

    Article  Google Scholar 

  • Rosenschein U, Roth A, Rassin T, Basan S, Laniado S, Miller HI (1997) Analysis of coronary ultrasound thrombolysis endpoints in acute myocardial infarction (ACUTE trial). Results of the feasibility phase. Circulation 95:1411–1416

    Article  PubMed  CAS  Google Scholar 

  • Roux S, Christeller S, Lüdin E (1992) Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 19:671–677

    Article  PubMed  CAS  Google Scholar 

  • Schafer Al, Adelman B (1985) Plasmin inhibition of platelet function and of arachidonic acid metabolism. J Clin Invest 75:456–461

    Article  PubMed  CAS  Google Scholar 

  • Schmid JH, Jackson DP, Conley CL (1962) Mechanism of action of thrombin on platelets. J Clin Invest 41:543–553

    Article  PubMed  CAS  Google Scholar 

  • Sharma B, Wyeth RP, Gimenez HJ, Franciosa JA (1986) Intracoronary prostaglandin Ei plus streptokinase in acute myocardial infarction. Am J Cardiol 58:1161–1166

    Article  PubMed  CAS  Google Scholar 

  • Siddiqi F, Odrljin TM, Fay PJ, Cox C, Francis CW (1998) Binding of tissue-plasminogen activator to fibrin: effect of ultrasound. Blood 91:2019–2025

    PubMed  CAS  Google Scholar 

  • Siegel RJ, Atar S, Fishbein MC, Brasch AV, Peterson TM, Nagai T, Pal D, Nishioka T, Chae J-S, Birnbaum Y, Zanelli C, Luo H (2000) Noninvasive, transthoracic, low-frequency ultrasound augments thrombolysis in a canine model of acute myocardial infarction. Circulation 101:2026–2029

    Article  PubMed  CAS  Google Scholar 

  • Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators (1995) Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 91:1923–1928

    Article  PubMed  CAS  Google Scholar 

  • Song X, Huhle G, Wang L, Hoffmann U, Harenberg J (1999) Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 100:1528–1532

    Article  PubMed  CAS  Google Scholar 

  • Stein B, Fuster V, Halperin JL, Chesebro JH (1989) Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk. Circulation 80:1501–1513

    Article  PubMed  CAS  Google Scholar 

  • Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D, and the TAMI Study Group (1989) Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 80:1222–1230

    Article  PubMed  CAS  Google Scholar 

  • Stürzebecher J (1991) Methods for determination of hirudin. Semin Thromb Hemost 17:99–102

    Article  PubMed  Google Scholar 

  • Taubman MB, Giesen PLA, Schecter AD, Nemerson Y (1999) Regulation of the procoagulant response to arterial injury. Thromb Haemost 82:801–805

    PubMed  CAS  Google Scholar 

  • Tcheng JE (2000) Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 139 (Suppl.):S38–S45

    Article  PubMed  CAS  Google Scholar 

  • The Dutch TIA Trial Study Group (1991) A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325:1261–1266

    Article  Google Scholar 

  • The European Myocardial Infarction Project Group (1993) Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 329:383–389

    Article  Google Scholar 

  • The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators (1994) Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631–1637

    Article  Google Scholar 

  • The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775–782

    Article  Google Scholar 

  • The GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622

    Article  Google Scholar 

  • The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682

    Article  Google Scholar 

  • The I.S.A.M. Study Group (1986) A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. N Engl J Med 314:1465–1471

    Article  Google Scholar 

  • The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360

    Google Scholar 

  • The RAPT Investigators (1994) Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 89:588–595

    Article  Google Scholar 

  • The SCATI Group (1989) Randomised controlled trial of subcutaneous calciumheparin in acute myocardial infarction. Lancet 2:182–186

    Google Scholar 

  • Thompson PL, Aylward PE, Federman J, Giles RW, Harris PJ, Hodge RL, Nelson GI, Thomson A, Tonkin AM, Walsh WF, for the National Heart Foundation of Australia Coronary Thrombolysis Group (1991) A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 83:1534–1542

    Article  PubMed  CAS  Google Scholar 

  • Théroux P, Pérez-Villa F, Waters D, Lésperance J, Shabani F, Bonan R (1995) Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 91:2132–2139

    Article  PubMed  Google Scholar 

  • Tomaru T, Uchida Y, Nakamura F, Sonoki H, Tsukamoto M, Sugimoto T (1989) Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: an angioscopic study. Am Heart J 117:275–281

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O’Neill WW, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group (1987) A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 317:581–588

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ, Lee KL, Kline EM, Pitt B, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group (1989b) Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol 14:877–884

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J (1994) Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 89:1557–1566

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM, and the TAMI Study Group (1989a) A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction (TAMI-3). Circulation 79:281–286

    Article  PubMed  CAS  Google Scholar 

  • Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ (1997) Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95:594–599

    Article  PubMed  CAS  Google Scholar 

  • Toschi V, Lettino M, Gallo R, Badimon JJ, Chesebro JH (1996) Biochemistry and biology of hirudin. Coron Artery Dis 7:420–428

    Article  PubMed  CAS  Google Scholar 

  • Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME (1998) Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation 97:26–33

    Article  PubMed  Google Scholar 

  • Van de Werf F, for the Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators (1997) A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 337:1124–1130

    Article  Google Scholar 

  • Vaughan DE, Van Houtte E, Declerck PJ, Collen D (1991) Streptokinase-induced platelet aggregation. Prevalence and mechanism. Circulation 84:84–91

    Article  PubMed  CAS  Google Scholar 

  • Verheugt FWA, Liem A, Zijlstra F, Marsh RC, Veen G, Bronzwaer JGF (1998) High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol 31:289–293

    Article  PubMed  CAS  Google Scholar 

  • Verstraete M (2000) Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 101:e76–e80

    Article  PubMed  CAS  Google Scholar 

  • von Essen R, Zeymer U, Tebbe U, Jessel A, Kwasny H, Mateblowski M, Niederer W, Wagner J, Mäurer W, von Leitner E-R, Haerten K, Roth M, Neuhaus K-L, for the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (1998) HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte. Coron Artery Dis 9:265–272

    Article  Google Scholar 

  • Wallentin L, for the Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group (1996) Low-molecular-weight heparin during instability in coronary artery disease. Lancet 347:561–568

    CAS  Google Scholar 

  • Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M, for the Myocardial Infarction Triage and Intervention Project Group (1993) Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA 270:1211–1216

    Article  PubMed  CAS  Google Scholar 

  • Webster MWI, Chesebro JH, Fuster V (1991) Antithrombotic therapy in acute myocardial infarction: enhancement of reocclusion, and prevention of thromboembolism. In: Gersh BJ, Rahimtoola SH (eds). Acute myocardial infarction, Elsevier, New York, pp 331–348

    Google Scholar 

  • Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Theroux P (1995) New antithrombotics. Chest 108 (Suppl):471S–485S

    Article  PubMed  CAS  Google Scholar 

  • Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86:385–391

    Article  PubMed  CAS  Google Scholar 

  • Weitz JI, Leslie B, Hudoba M (1998) Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 97:544–552

    Article  PubMed  CAS  Google Scholar 

  • White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, Hillis WS, Shalev Y, French JK, Collins R, Maraganore J, Adelman B, on behalf of the Hirulog Early Reperfusion/ Occlusion (HERO) trial Investigators (1997) Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 96:2155–2161

    Article  PubMed  CAS  Google Scholar 

  • Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET Study Group (1988) Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 2:525–530

    Article  PubMed  CAS  Google Scholar 

  • Wysokinski W, McBane R, Chesebro JH, Owen WG (1996) Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries. Thromb Haemost 76:1108–1113

    PubMed  CAS  Google Scholar 

  • Young E, Podor TJ, Venner T, Hirsh J (1997) Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vase Biol 17:1568–1574

    Article  CAS  Google Scholar 

  • Zeymer U, von Essen R, Tebbe U, Michels H-R, Jessel A, Vogt A, Roth M, Appel K-F, Neuhaus K-L (1995) Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis). Eur Heart J 16 (Suppl D):22–27

    Article  PubMed  CAS  Google Scholar 

  • Zhu Y, Carmeliet P, Fay WP (1999) Plasminogen activator inhibitor-1 is a major determinant of arterial throm321bolysis resistance. Circulation 99:3050–3055

    Article  PubMed  CAS  Google Scholar 

  • Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH (1994) Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 90:2671–2678

    Article  PubMed  CAS  Google Scholar 

  • Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH (1993) Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 88 [Part 1]:2015–2022

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. Hayes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Gallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Fuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Chesebro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. FRAT — Hôpital Nestlé 2077, CHUV, CH-1011, Lausanne, Switzerland

    F. Bachmann

  2. Chemin Praz Mandry 20, CH-1052, Le Mont, Switzerland

    F. Bachmann

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hayes, R., Gallo, R., Fuster, V., Chesebro, J. (2001). Conjunctive Therapy to Reduce the Occurrence of Coronary Reocclusion after Thrombolytic Treatment of AMI. In: Bachmann, F. (eds) Fibrinolytics and Antifibrinolytics. Handbook of Experimental Pharmacology, vol 146. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56637-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56637-0_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63029-3

  • Online ISBN: 978-3-642-56637-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation